NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.7100
-0.0008 (-0.11%)
Apr 14, 2026, 4:00 PM EDT - Market closed
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
25.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences | 34 |
| Boundless Bio | 28 |
| Daré Bioscience | 24 |
| Tevogen Bio Holdings | 18 |
| Outlook Therapeutics | 17 |
| Barinthus Biotherapeutics | 14 |
| Serina Therapeutics | 13 |
| Skye Bioscience | 12 |
NRSN News
- 8 days ago - NeuroSense Granted Brazilian Patent Covering PrimeC Composition - PRNewsWire
- 11 days ago - NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - PRNewsWire
- 14 days ago - NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update - PRNewsWire
- 21 days ago - NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout - PRNewsWire
- 27 days ago - PrimeC New Data to Be Presented at AD/PD™ 2026 Conference - PRNewsWire
- 4 weeks ago - JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity - PRNewsWire
- 5 weeks ago - PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - PRNewsWire
- 7 weeks ago - NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS - PRNewsWire